Double-stranded rnai agents and compositions for reducing expression of angiopoietin-like 3 (angptl3) and methods of use thereof
US-2026092279-A1 · Apr 2, 2026 · US
Silence Therapeutics Gmbh holds 84 patents in our database, with recent filings and technology areas summarized below.
| Metric | Value |
|---|---|
| Total patents | 84 |
| Recent patents | 19 |
| First publication | Jul 14, 2015 |
| Latest publication | Apr 2, 2026 |
Year-over-year patent counts for this assignee.
Latest publications where this party is an assignee.
US-2026092279-A1 · Apr 2, 2026 · US
US-2026078372-A1 · Mar 19, 2026 · US
US-2025230441-A1 · Jul 17, 2025 · US
US-2025163415-A1 · May 22, 2025 · US
US-2025136977-A1 · May 1, 2025 · US
Representative or frequently cited publications from precomputed assignee stats.
US-2026092279-A1 · Apr 2, 2026 · US
US-2026078372-A1 · Mar 19, 2026 · US
US-2025230441-A1 · Jul 17, 2025 · US
US-2025163415-A1 · May 22, 2025 · US
US-2025136977-A1 · May 1, 2025 · US
Most common classification codes in this portfolio.
| CPC | Patents |
|---|---|
| C12N2310/14 | 79 |
| C12N15/113 | 70 |
| C12N2310/321 | 69 |
| C12N2310/322 | 61 |
| A61K31/713 | 54 |
Mapped technology topics for this assignee.
| Technology | Patents |
|---|---|
| Chemistry & Metallurgy | 82 |
| Human Necessities | 79 |
| Physics | 4 |
| Cross-Sectional Technologies | 4 |
Answers are generated from the same data shown on this page.